Glenmark released Picture Post Cards on World Vitiligo Day
The company has been entrusted with the responsibility of supplying a wide range of essential oncology drugs
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
These abstracts report on the company's three lead drug candidates, including olverembatinib
Subscribe To Our Newsletter & Stay Updated